Abstract: Pathological myopia-induced choroidal neovascularization (PM-CNV) can severely lead to irreversible central vision loss, affecting the quality of life of patients. Its onset is related to the combined effects of mechanical traction on the retina and choroid caused by excessive axial length, abnormal hemodynamics, and genetic factors. Currently, anti-VEGF drugs have become the standard first-line treatment for PM-CNV, but their long-term efficacy is not satisfactory, and repeated administration poses a risk of retinal and choroidal atrophy and thinning. Currently, some new drugs with stronger and more lasting effects for PM-CNV are undergoing basic research and clinical trials.(Int Rev Ophthalmol, 2025, 49:  129-134)

Key words: pathological myopia, choroidal neovascularization